Cupid Limited enters its Q4 FY26 earnings release following a period of rapid expansion across its sexual wellness, FMCG, and diagnostics divisions. Investors are closely watching the company's ability to sustain its record-breaking margin trajectory while simultaneously scaling its Palava manufacturing facility and executing on strategic retail investments.
| Results date | 2026-05-15 |
|---|---|
| Quarter | Q4 FY26 |
| Previous quarter revenue | Rs. 93.50 Cr |
| Previous quarter PAT | Rs. 32.83 Cr |
| Previous quarter EBITDA margin | 37% |
| Market cap | Rs. 16687.26 Cr |
| CMP | Rs. 124.1 |
The company has scheduled a board meeting for May 15, 2026, to consider and approve the audited financial results for Q4 and FY26.
In its most recently reported quarter, Cupid Limited posted revenue of Rs. 93.50 Cr, PAT of Rs. 32.83 Cr, and an EBITDA margin of 37%. The company is maintaining strong momentum in its B2C segment, which reached a revenue contribution of 14% in FY25, as it works toward its FY26 B2C revenue target of Rs. 125 Cr. Management has highlighted that the order book is at its highest level to date, with the South Africa 5-year program contributing an annual allocation of approximately Rs. 115 Cr through 2030. Furthermore, the diagnostics business continues to scale, with a current capacity of 1.5 lakh kits per day and a target to reach 4 lakh kits per day by the end of 2026.
Performance vs Guidance Tracking: Tracking progress against FY26 financial and operational targets.
Strategic Updates: Key project milestones and expansion progress.
Operational Focus Areas: Key business drivers and market expansion.
Risks and headwinds to monitor: Management-flagged operational and regulatory risks.
Cupid Limited will announce its Q4 FY 2025-2026 results on May 15, 2026.
In Q3 FY26, Cupid Limited reported revenue from operations of Rs. 93.50 Cr.
Cupid Limited's current market capitalisation is Rs. 16,687.26 Cr.
The Palava manufacturing facility is targeted for commissioning by the end of CY2026. This facility is expected to add 770 million male condoms and 75 million female condoms to annual capacity.
Yes, the company is tracking ahead of its FY26 revenue guidance of Rs. 335 Cr. The company reported Rs. 259.36 Cr in revenue for the first nine months of the financial year.
Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings
Login Now